NCT03827876 - Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

September 15, 2019

Study Completion Date

December 15, 2019

Conditions

Psoriasis

Interventions

DRUG

Enstilar 0.005%-0.064% Topical Foam

Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

Trial Locations (1)

RECRUITING

Psoriasis Treatment Center of Central New Jersey, East Windsor